CN102471313B - Gpr119激动剂 - Google Patents

Gpr119激动剂 Download PDF

Info

Publication number
CN102471313B
CN102471313B CN201080031375.4A CN201080031375A CN102471313B CN 102471313 B CN102471313 B CN 102471313B CN 201080031375 A CN201080031375 A CN 201080031375A CN 102471313 B CN102471313 B CN 102471313B
Authority
CN
China
Prior art keywords
mmol
mixture
added
compound
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080031375.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102471313A (zh
Inventor
D·G·巴莱特
J·B·弗朗西斯科维奇
刘斌
K·塔克乌奇
A·B·布埃诺梅伦多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102471313(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102471313A publication Critical patent/CN102471313A/zh
Application granted granted Critical
Publication of CN102471313B publication Critical patent/CN102471313B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201080031375.4A 2009-07-15 2010-07-12 Gpr119激动剂 Expired - Fee Related CN102471313B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382114.8 2009-07-15
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
US61/245,445 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (2)

Publication Number Publication Date
CN102471313A CN102471313A (zh) 2012-05-23
CN102471313B true CN102471313B (zh) 2014-06-04

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080031375.4A Expired - Fee Related CN102471313B (zh) 2009-07-15 2010-07-12 Gpr119激动剂

Country Status (24)

Country Link
US (1) US8207344B2 (cg-RX-API-DMAC7.html)
EP (1) EP2454251A1 (cg-RX-API-DMAC7.html)
JP (1) JP5715127B2 (cg-RX-API-DMAC7.html)
KR (1) KR101365854B1 (cg-RX-API-DMAC7.html)
CN (1) CN102471313B (cg-RX-API-DMAC7.html)
AR (1) AR077638A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010273642B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015921A2 (cg-RX-API-DMAC7.html)
CA (1) CA2764906C (cg-RX-API-DMAC7.html)
CO (1) CO6480977A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120012A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000006A (cg-RX-API-DMAC7.html)
EA (1) EA020540B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011606A (cg-RX-API-DMAC7.html)
IL (1) IL216776A0 (cg-RX-API-DMAC7.html)
MA (1) MA33428B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012000704A (cg-RX-API-DMAC7.html)
NZ (1) NZ597125A (cg-RX-API-DMAC7.html)
PE (1) PE20121045A1 (cg-RX-API-DMAC7.html)
SG (1) SG177646A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000002A1 (cg-RX-API-DMAC7.html)
TW (1) TWI429634B (cg-RX-API-DMAC7.html)
WO (1) WO2011008663A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200227B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) * 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013048916A1 (en) * 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
CA2855009C (en) 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013187646A1 (en) * 2012-06-12 2013-12-19 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
HUE045926T2 (hu) 2013-11-26 2020-01-28 Chong Kun Dang Pharmaceutical Corp Amid-származékok GPR119 agonistákhoz
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025798A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (sr) * 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025798A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioisosterism A Rational Approach in Drug Design;George A. Patani, et al;《Chem. Rev.》;19961231;第96卷(第8期);3147-3176 *

Also Published As

Publication number Publication date
TWI429634B (zh) 2014-03-11
WO2011008663A1 (en) 2011-01-20
MA33428B1 (fr) 2012-07-03
TW201114757A (en) 2011-05-01
NZ597125A (en) 2013-08-30
JP5715127B2 (ja) 2015-05-07
KR20120024964A (ko) 2012-03-14
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23
KR101365854B1 (ko) 2014-02-21
AU2010273642A1 (en) 2012-01-19
CA2764906A1 (en) 2011-01-20
PE20121045A1 (es) 2012-08-09
ECSP12011606A (es) 2012-02-29
AR077638A1 (es) 2011-09-14
DOP2012000006A (es) 2012-01-31
EA201270169A1 (ru) 2012-06-29
TN2012000002A1 (en) 2013-09-19
US8207344B2 (en) 2012-06-26
SG177646A1 (en) 2012-02-28
CO6480977A2 (es) 2012-07-16
ZA201200227B (en) 2013-06-26
MX2012000704A (es) 2012-03-07
CA2764906C (en) 2014-06-10
IL216776A0 (en) 2012-03-01
EA020540B1 (ru) 2014-11-28
EP2454251A1 (en) 2012-05-23
JP2012533546A (ja) 2012-12-27
US20110015199A1 (en) 2011-01-20
AU2010273642B2 (en) 2014-03-13
CR20120012A (es) 2012-03-28

Similar Documents

Publication Publication Date Title
CN102471313A (zh) Gpr119激动剂
KR102397720B1 (ko) 암을 치료하기 위한 방법
EA011671B1 (ru) Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
BRPI0708264A2 (pt) piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
JP5718236B2 (ja) 5−ヒドロキシピリミジン−4−カルボキサミド誘導体
CN101115740A (zh) 作为代谢调节剂的经取代吡啶基和嘧啶基衍生物和相关疾病的治疗
WO2022042711A1 (zh) 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体
TWI394752B (zh) 作為組蛋白去乙醯基酶的新穎抑制劑之經取代的丙烯基六氫吡衍生物
EP1716135B1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
WO2013147214A1 (ja) 5-ヒドロキシピリミジン-4-カルボキサミド誘導体
CN106660998B (zh) 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂
HK40082933A (en) Acetophenone oxime compound and application thereof
HK1148006A1 (en) Isoquinoline modulators of atp-binding cassette transporters
HK1148006B (en) Isoquinoline modulators of atp-binding cassette transporters
HK1177137B (en) Isoquinoline modulators of atp-binding cassette transporters

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140604

Termination date: 20160712